8-K

================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                ------------------

                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): FEBRUARY 20, 2003

                                  BIOGEN, INC.
               (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

       MASSACHUSETTS                   0-12042                  04-3002117
(STATE OR OTHER JURISDICTION         (COMMISSION             (I.R.S. EMPLOYER
      OF INCORPORATION)              FILE NUMBER)           IDENTIFICATION NO.)

                            FOURTEEN CAMBRIDGE CENTER
                         CAMBRIDGE, MASSACHUSETTS 02142
                    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

                                ------------------

                                 (617) 679-2000
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

                                ------------------

================================================================================



ITEM 5.  OTHER EVENTS AND REGULATION FD DISCLOSURE.

         On February 20, 2003, the Registrant publicly disseminated a press
release announcing that the Registrant has decided to withdraw its application
for approval of AMEVIVE(R) (alefacept) for psoriasis in the European Union
because the Committee for Proprietary Medicinal Products, the scientific
advisory body of the European Medicines Evaluation Agency, determined that more
clinical information is needed to approve the product. The information contained
in the press release is incorporated herein by reference and filed as Exhibit
99.1 hereto.

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS.

(c)      Exhibits.

99.1     The Registrant's Press Release dated February 20, 2003.



                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    BIOGEN, INC.

                                    By:/s/ Anne Marie Cook
                                    -----------------------------------------
                                       Anne Marie Cook
                                       Vice President,Chief Corporate Counsel

                                       Dated: February 24, 2003



                                  EXHIBIT INDEX



- ---------------   ---------------------------------------------------------
Exhibit Number    Description
- ---------------   ---------------------------------------------------------
               
99.1              The Registrant's Press Release dated February 20, 2003
- ---------------   ---------------------------------------------------------

EX-99.1

                                  EXHIBIT 99.1

                     EUROPEAN APPROVAL OF AMEVIVE(R) DELAYED

               Committee Requests Additional Clinical Information

Cambridge, MA (February 20, 2003) - Biogen, Inc. (NASDAQ/BGEN) announced today
that the Committee for Proprietary Medicinal Products (CPMP), the scientific
advisory body of the European Medicines Evaluation Agency (EMEA), requested more
information relating to its application for AMEVIVE(R) (alefacept) for
psoriasis. In the final assessment received this week, the CPMP determined that
more clinical information is needed to approve the product. Biogen has withdrawn
its application and plans to develop the additional clinical information
necessary to obtain approval of AMEVIVE for psoriasis patients in Europe.
Developing the data and re-filing the application to gain approval could take
several years.

This action should have no impact on the company's 2003 financial guidance.
Biogen will be evaluating the impact on guidance for 2004 and beyond,
considering the delay of European revenue as well as sales and marketing
expense, and updating this outlook in its quarterly earnings call.

ABOUT BIOGEN

Biogen is the world's oldest independent biotechnology company and a leader in
biologics research, development and manufacturing. A pioneer in leading edge
research in immunology, neurobiology and oncology, Biogen brings novel therapies
to improve patients' lives around the world through its global marketing
capabilities. For press releases and additional information about the company,
please visit http://www.biogen.com.

SAFE HARBOR

In addition to historical information, this press release contains
forward-looking statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. Reference is made in
particular to plans for the development of additional clinical data in response
to the determination of the Committee for Proprietary Medicinal Products (CPMP)
and the Company's expectations regarding the impact of the decision on financial
results. These statements are based on the Company's current beliefs and
expectations as to such future outcomes. There is no assurance that the Company
will be able to generate data satisfactory to the CPMP. There are also a number
of risks and uncertainties that could cause actual financial results to differ
materially from our expectations. For example, financial results may be affected
by the impact of competitive products on AVONEX (interferon beta-1a) sales, any
slowing of growth of the multiple sclerosis market, any change in market
acceptance of AVONEX in key markets worldwide, the level of success in launching
AMEVIVE in the United States and the impact on expenses of development, sales
and marketing



activities and in-licensing and product opportunities as well as the other risks
and uncertainties described from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission.

CONFERENCE CALL AND WEBCAST
The company will host a call for investors at 9:00 a.m. EST on February 20,
2003, and will be accessible through the investor relations section of Biogen's
homepage, http://www.biogen.com.